spacer
home > ict > autumn 2009 > database dynamics
PUBLICATIONS
International Clinical Trials

Database Dynamics

 

The pharmaceutical industry today faces a perfect storm of events that are challenging its ability to bring new drugs to market. Drug companies are seeing fewer new drugs entering the market worldwide, R&D productivity is slipping, clinical trials costs are escalating, and senior drug development executives are seeking new strategies to increase the number of successfully completed clinical trials. For many pharmaceutical companies, CROs are an important part of their drug development efforts. They represent an essential, and growing, force in the effort to develop new products efficiently and economically. A recent survey of pharmaceutical professionals involved in CRO outsourcing and project management demonstrates the importance of implementation detail in the selection of a CRO when they conduct one or more studies for a sponsor company. This article demonstrates how a CRO can use clinical grants to illustrate this implementation detail during both the project selection and project conduct portions of clinical studies.

Today, CRO use is on the rise. In survey after survey, pharmaceutical company and CRO respondents say that they expect to see more outsourcing (1). Moreover, many companies think CROs provide great flexibility. They can be used in a wide variety of ways, from a preferred provider with responsibility for conducting almost all of a company’s clinical trial activity, to just one of many CROs bidding to conduct a portion of one clinical trial. Whichever way sponsor companies choose to use CROs, most clinical development professionals expect their use to expand greatly in the years ahead.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Currently serving in the role of Clinical Site Agreements Consultant for PAREXEL International, LLC, Keitia Brooks has been in contracts management for over 10 years within the private and public sectors, which includes the healthcare and government industries. Keitia’s primary focus is the development of the CRO’s global investigator grant estimates for their clients and sponsors.

Jeanelle Pierre is a Senior Client Manager at TTC, llc, which provides clinical trial benchmark information to the pharmaceutical industry. In this position Jeanelle’s knowledge of international outsourcing and clinical development continues to guide the product and its utilisation among industry leaders. With her BSc in Computer Programming she has been able to provide guidance in system development, including management of TTC’s latest benchmarking tool for IITs.

spacer
Keitia Brooks
spacer
spacer
spacer
Jeanelle Pierre
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Restructure Announcement at Illingworth

As a rapidly growing company, Illingworth Research Group (Illingworth) has reflected on its goals, accomplishments and ambitious future growth plans. This has allowed us to consider opportunities for staff to explore their own growth and development possibilities within a rapidly changing landscape. With that in mind, Illingworth are announcing some significant and exciting changes to our organization. Illingworth remain committed to making patient involvement in clinical trials as stress free as possible and our strengthened management team and launch of our patient concierge service, PatientGO, in combination with global, mobile research nursing will ensure as many patients as possible have the chance to participate in the development of critical drugs, regardless of their geography or socioeconomic class.
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement